Quantum Cyber N.V. current report, Q4 FY2024

Business Context and Reporting Period

This Form 6-K filing by Mainz Biomed N.V. (noted as Quantum Cyber N.V. in metadata) covers the month of December 2024. The report details the closing of a follow-on equity offering on December 16, 2024, involving the sale of ordinary units and pre-funded units to an institutional investor.

Key Financial Metrics

  • Gross Proceeds: Approximately $8,000,000 before deducting placement agent fees and offering expenses.
  • Offering Price: $5.85 per ordinary unit; $5.85 less $0.0001 per pre-funded unit.
  • Placement Agent Fees: 7% of gross proceeds plus a fixed fee of $100,000.
  • Units Sold: 220,165 ordinary units and 1,147,356 pre-funded units.
  • Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational financial metrics.

Material Changes

The primary material change is the increase in capital raised through the Offering. The Company entered into a Securities Purchase Agreement (SPA) on December 12, 2024, which closed on December 16, 2024. This transaction significantly alters the Company's capital structure through the issuance of new shares and warrants.

Outlook, Risks, and Unusual Items

  • Warrant Terms:
    • Class A Warrants: Exercise price of $5.85; expire five years from issuance.
    • Class B Warrants: Exercise price of $5.85; expire on the earlier of 30 days following the eAArly Detect 2 study results or one year from issuance.
    • Pre-Funded Warrants: Immediately exercisable at $0.001 per share.
  • Anti-Dilution Provisions: Class A and Class B warrants include protections for stock dividends, splits, and subsequent financings at prices below the current exercise price.
  • Management Commentary: The filing references a press release titled "Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering" but does not include specific forward-looking statements or risk factors within the body of this text.

Investor Verification Checklist

  • Verify the net proceeds after deducting the 7% placement fee and the $100,000 fixed fee.
  • Confirm the dilution impact of the 1,147,356 pre-funded units and associated warrants.
  • Monitor the timeline for the "eAArly Detect 2 study" results, as this triggers the expiration of Class B Warrants.
  • Review the full Registration Statement on Form F-1 (no. 333-282993) for detailed warrant terms and risk factors.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.